New combo therapy shows promise for rare, aggressive thyroid cancer
NCT ID NCT04171622
First seen Feb 18, 2026 · Last updated May 23, 2026 · Updated 13 times
Summary
This study tests whether combining lenvatinib (a drug that blocks cancer cell growth) with pembrolizumab (an immunotherapy that helps the immune system attack cancer) can help people with advanced anaplastic thyroid cancer that cannot be removed by surgery or has spread. The trial includes 25 participants and focuses on how long they live and how long the cancer stays under control. The goal is to see if the combination works better than either drug alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID GLAND SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.